TY - JOUR
T1 - Molecular recognition of glyconanoparticles by RCA and E. coli K88 - Designing transports for targeted therapy
AU - Gallegos-Tabanico, Amed
AU - Sarabia-Sainz, Jose A.
AU - Sarabia-Sainz, H. Manuel
AU - Torres, Roberto Carrillo
AU - Guzman-Partida, Ana M.
AU - Monfort, Gabriela Ramos Clamont
AU - Silva-Campa, Erika
AU - Burgara-Estrella, Alexel J.
AU - Angulo-Molina, Aracely
AU - Acosta-Elias, Mónica
AU - Pedroza-Montero, Martín
AU - Vazquez-Moreno, Luz
PY - 2017
Y1 - 2017
N2 - The targeted drug delivery has been studied as one of the main methods in medicine to ensure successful treatments of diseases. Pharmaceutical sciences are using micro or nano carriers to obtain a controlled delivery of drugs, able to selectively interact with pathogens, cells or tissues. In this work, we modified bovine serum albumin (BSA) with lactose, obtaining a neoglycan (BSA-Lac). Subsequently, we synthesized glyconanoparticles (NPBSA-Lac) with the premise that it would be recognized by microbial galactose specific lectins. NPBSA- Lac were tested for bio-recognition with adhesins of E. coli K88 and Ricinus communis agglutinin I (RCA). Glycation of BSA with lactose was analyzed by electrophoresis, infrared spectroscopy and fluorescence. Approximately 41 lactoses per BSA molecule were estimated. Nanoparticles were obtained using water in oil emulsion method and spheroid morphology with a range size of 300-500 nm was observed. Specific recognition of NPBSA- Lac by RCA and E. coli K88 was displayed by aggregation of nanoparticles analyzed by dynamic light scattering and atomic force microscopy. The results indicate that the lactosylated nanovectors could be targeted at the E. coli K88 adhesin and potentially could be used as a transporter for an antibacterial drug.
AB - The targeted drug delivery has been studied as one of the main methods in medicine to ensure successful treatments of diseases. Pharmaceutical sciences are using micro or nano carriers to obtain a controlled delivery of drugs, able to selectively interact with pathogens, cells or tissues. In this work, we modified bovine serum albumin (BSA) with lactose, obtaining a neoglycan (BSA-Lac). Subsequently, we synthesized glyconanoparticles (NPBSA-Lac) with the premise that it would be recognized by microbial galactose specific lectins. NPBSA- Lac were tested for bio-recognition with adhesins of E. coli K88 and Ricinus communis agglutinin I (RCA). Glycation of BSA with lactose was analyzed by electrophoresis, infrared spectroscopy and fluorescence. Approximately 41 lactoses per BSA molecule were estimated. Nanoparticles were obtained using water in oil emulsion method and spheroid morphology with a range size of 300-500 nm was observed. Specific recognition of NPBSA- Lac by RCA and E. coli K88 was displayed by aggregation of nanoparticles analyzed by dynamic light scattering and atomic force microscopy. The results indicate that the lactosylated nanovectors could be targeted at the E. coli K88 adhesin and potentially could be used as a transporter for an antibacterial drug.
KW - Bio-recognition
KW - Bovine serum albumin
KW - Drug delivery
KW - Nanoparticles
KW - Neoglycan
UR - http://www.scopus.com/inward/record.url?scp=85039158377&partnerID=8YFLogxK
U2 - 10.18388/abp.2017_1639
DO - 10.18388/abp.2017_1639
M3 - Artículo
SN - 0001-527X
VL - 64
SP - 671
EP - 677
JO - Acta Biochimica Polonica
JF - Acta Biochimica Polonica
IS - 4
ER -